<DOC>
	<DOC>NCT01048593</DOC>
	<brief_summary>This study will test the efficacy and safety of IBI-10090 for the reduction of ocular inflammation after cataract surgery.</brief_summary>
	<brief_title>Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery</brief_title>
	<detailed_description>All patients received active treatment in this study. Dose group 1 received 114ug of dexamethasone, Dose group 2 received 513ug and Dose group 3 received 684ug.</detailed_description>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<criteria>Male or female patients 40 years of age scheduled for unilateral cataract surgery (phacoemulsification or extracapsular extraction) with posterior chamber intraocular lens implantation. Patients who have used any ocular, topical or oral corticosteroids within 7 days prior to Day 0. Patients who have used topical ocular NSAIDs in the study eye within 15 days prior to screening. Patients with any signs of intraocular inflammation in either eye at screening. Patients who have received any prior intravitreal injections in the study eye.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>ocular inflammation cataract surgery</keyword>
	<keyword>post cataract surgery inflammation</keyword>
</DOC>